Table 2 irAEs occurrence according to the system/organ involved
From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts
Any grade irAEs | Early-irAEs (patients-%) | Late-irAEs (patients-%) | P value |
|---|---|---|---|
Overall population | 175 (55.0) | 110 (34.6) | 0.0013 |
 Skin | 68 (38.9) | 45 (40.9) | 0.8212 |
 Endocrine | 49 (28.0) | 17 (15.4) | 0.0508 |
 Gastrointestinal | 39 (22.3) | 15 (13.6) | 0.1314 |
 Pneumological | 12 (6.9) | 7 (6.4) | 0.8792 |
 Haepatic | 8 (4.6) | 3 (2.7) | 0.5411 |
 Rheumatologic | 37 (21.1) | 26 (23.6) | 0.6943 |
 Neurologic | 1 (0.6) | 7 (6.4) | 0.0076 |
 Others | 47 (26.9) | 11 (10.0) | 0.0044 |
G3/G4 irAEs | 13 (4.1) | 12 (3.8) | 0.8446 |